Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 50127T109 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
Biotechnology Value Fund L P
13G/A
|
10.0% |
11/14/2025
Event 9/30/2025
|
||
| Biotechnology Value Fund L P | 5.1% | |||
| BVF I GP LLC | 5.1% | |||
| Biotechnology Value Fund II LP | 4.2% | |||
| BVF II GP LLC | 4.2% | |||
| Biotechnology Value Trading Fund OS LP | 0.5% | |||
| BVF Partners OS Ltd. | 0.5% | |||
| BVF GP Holdings LLC | 9.3% | |||
| BVF Partners L P/IL | 10.0% | |||
| BVF Inc/IL | 10.0% | |||
| Lampert Mark N | 10.0% | |||
|
Montanova Capital, LLC
13G/A
|
9.7% |
8/14/2026
Event 6/30/2026
|
||
| Montanova Capital, LLC | 9.7% | |||
| Averill Master Fund, Ltd. | 8.8% | |||
| Aaron Cowen | 9.7% | |||
| BlackRock, Inc. 13G/A | 7.8% |
4/17/2025
Event 3/31/2025
|
||
| State Street Corp 13G | 5.7% |
2/9/2026
Event 12/31/2025
|
||
| Vanguard Capital Management LLC 13G | 5.0% |
4/30/2026
Event 3/31/2026
|
||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (6) | ||||
|
RA Capital Management, L.P.
13G/A
|
4.9% |
5/15/2025
Event 3/31/2025
|
||
| RA Capital Management, L.P. | 4.9% | |||
| Peter Kolchinsky | 4.9% | |||
| Rajeev Shah | 4.9% | |||
| RA Capital Healthcare Fund, L.P. | 4.9% | |||
|
EcoR1 Capital, LLC
13G/A
|
4.8% |
8/14/2025
Event 6/30/2025
|
||
| EcoR1 Capital, LLC | 4.8% | |||
| Oleg Nodelman | 4.8% | |||
| EcoR1 Capital Fund Qualified, L.P. | 4.5% | |||
|
Armistice Capital, LLC
13G/A
|
4.2% |
5/15/2026
Event 3/31/2026
|
||
| Armistice Capital, LLC | 4.2% | |||
| Steven Boyd | 4.2% | |||
|
James E. Flynn
13G/A
|
0% |
2/13/2025
Event 12/31/2024
|
||
| Deerfield Mgmt, L.P. | 0% | |||
| Deerfield Management Company, L.P. | 0% | |||
| Deerfield Partners, L.P. | 0% | |||
| James E. Flynn | 0% | |||
|
Paradigm Biocapital Advisors LP
13G/A
|
0% |
2/14/2025
Event 12/31/2024
|
||
| Paradigm BioCapital Advisors LP | 0% | |||
| Paradigm BioCapital Advisors GP LLC | 0% | |||
| Senai Asefaw, M.D. | 0% | |||
| Paradigm BioCapital International Fund Ltd. | 0% | |||
| Vanguard Group Inc 13G/A | 0% |
3/27/2026
Event 3/13/2026
|
||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 5 | 4.85 k | $51.9 k |
| 2026 Q2 | 231 | 88.2 M | $1.05 B |
| 2026 Q1 | 232 | 84.7 M | $689 M |
| 2025 Q4 | 227 | 85.4 M | $889 M |
| 2025 Q3 | 210 | 83.9 M | $743 M |
| 2025 Q2 | 189 | 82.2 M | $474 M |
| 2025 Q1 | 191 | 80.5 M | $531 M |
| 2024 Q4 | 192 | 78.8 M | $686 M |
| 2024 Q3 | 188 | 82.9 M | $1.62 B |
| 2024 Q2 | 187 | 82.2 M | $1.69 B |
| 2024 Q1 | 180 | 83.9 M | $1.79 B |
| 2023 Q4 | 148 | 81.1 M | $1.17 B |
| 2023 Q3 | 138 | 75.3 M | $687 M |
| 2023 Q2 | 157 | 75.1 M | $795 M |
| 2023 Q1 | 148 | 72.7 M | $888 M |
| 2022 Q4 | 153 | 74.6 M | $926 M |
| 2022 Q3 | 160 | 72.5 M | $990 M |
| 2022 Q2 | 160 | 69.0 M | $1.27 B |
| 2022 Q1 | 161 | 67.1 M | $1.12 B |
| 2021 Q4 | 169 | 64.4 M | $902 M |
| 2021 Q3 | 162 | 66.7 M | $1.25 B |
| 2021 Q2 | 182 | 67.8 M | $1.41 B |
| 2021 Q1 | 180 | 68.6 M | $1.94 B |
| 2020 Q4 | 221 | 65.8 M | $2.15 B |
| 2020 Q3 | 174 | 53.8 M | $1.65 B |
| 2020 Q2 | 142 | 52.8 M | $861 M |
| 2020 Q1 | 124 | 42.8 M | $424 M |
| 2019 Q4 | 132 | 39.6 M | $544 M |
| 2019 Q3 | 118 | 40.2 M | $610 M |
| 2019 Q2 | 127 | 38.9 M | $765 M |
| 2019 Q1 | 110 | 32.4 M | $536 M |
| 2018 Q4 | 101 | 32.8 M | $460 M |
| 2018 Q3 | 123 | 30.4 M | $532 M |
| 2018 Q2 | 112 | 29.8 M | $542 M |
| 2018 Q1 | 99 | 23.7 M | $444 M |
| 2017 Q4 | 76 | 19.5 M | $299 M |
| 2017 Q3 | 67 | 19.5 M | $292 M |
| 2017 Q2 | 44 | 10.8 M | $101 M |
| 2017 Q1 | 36 | 10.7 M | $94.5 M |
| 2016 Q4 | 31 | 10.0 M | $59.2 M |
| 2016 Q3 | 28 | 9.75 M | $60.9 M |
| 2016 Q2 | 25 | 9.32 M | $25.2 M |
| 2016 Q1 | 20 | 10.2 M | $41.4 M |
| 2015 Q4 | 14 | 10.2 M | $86.1 M |